ASPEN PHARMACARE HOLDINGS LIMITED Inactive Instrument
Aspen Pharmacare Holdings Limited Share Price Other OTC
Equities
APNHY
US04530Y1064
Pharmaceuticals
| Sales 2024 * | 44.56B 2.41B 201B | Sales 2025 * | 50.72B 2.74B 229B | Capitalization | 101B 5.48B 457B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.23B 337M 28.09B | Net income 2025 * | 8.46B 457M 38.15B | EV / Sales 2024 * | 2.77 x |
| Net Debt 2024 * | 21.9B 1.18B 98.8B | Net Debt 2025 * | 19.08B 1.03B 86.05B | EV / Sales 2025 * | 2.37 x |
| P/E ratio 2024 * |
17.4
x | P/E ratio 2025 * |
12.1
x | Employees | - |
| Yield 2024 * |
1.54% | Yield 2025 * |
1.87% | Free-Float | 60.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aspen Pharmacare Holdings Limited
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Saad
FOU | Founder | 60 | - |
Sean Capazorio
DFI | Director of Finance/CFO | 57 | 01/99/01 |
| Chief Operating Officer | 60 | 01/99/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 01/99/01 | |
Stephen Saad
FOU | Founder | 60 | - |
Kuseni Dlamini
CHM | Chairman | 53 | 01/12/01 |
Aspen Pharmacare Holdings Limited is the African leading pharmaceutical group. The group's products are primarily for the treatment of asthma, HIV, bacterial infections, gastro-intestinal, respiratory and inflammatory diseases. Net sales break down by family of products as follows:
- pharmaceuticals (71.6%): anaesthetics products, thrombosis products, cytotoxic products, etc.;
- other (28.4%): infant nutrition products and consumer products.
At the end of June 2022, the group had 16 production sites worldwide.
Sector
Pharmaceuticals
Calendar
03/09/2024
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +19.98% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +14.32% | 13.79B | |
| +44.72% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| -2.27% | 4.81B |
